+32.3%
GSK vs SARO
-14.3%
+46.6%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | SARO | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -1.4% | +1.3% | 0.0% |
| 7D | -5.3% | -4.2% | -1.1% | -5.0% |
| 30D | -3.7% | +23.9% | -27.5% | -5.4% |
| 3M | -7.3% | +5.3% | -12.6% | -7.8% |
| 6M | -4.2% | +0.4% | -4.6% | -4.7% |
| YTD | +0.9% | -7.4% | +8.2% | +0.6% |
| 1Y | +7.3% | +9.5% | -2.2% | +6.0% |
| All | +32.3% | -14.3% | +46.6% | +26.6% |
Cumulative growth
Daily Returns
Daily percentage return beside SARO.
Daily Out/Under-Performance
Portfolio return minus SARO return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × SARO return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded SARO wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling